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Abstract

Genetic analysis of the biosynthesis of pharmaceutically important dihydroergot alkaloids by
heterologous expression of Claviceps gigantea genes in the fungus Neosartorya fumigata

Ergot alkaloids are a family of secondary metabolites produced by several species of fungi. The
structural similarities of ergot alkaloids to neurotransmitters give them the ability to help treat
several neurological and cognitive diseases, such as dementia, Alzheimer’s and Parkinson’s
disease. These pharmaceuticals are currently being synthesized from more complex ergot
alkaloids, however they would be more efficiently synthesized from dihydroergot alkaloids.
Understanding the genes involved in the synthesis of dihydroergot alkaloids, such as
dihydrolysergol and dihydrolysergic acid, and elucidating their pathways will be beneficial. The
Mexican maize ergot pathogen Claviceps gigantea has been reported to produce dihydrolysergol,
which is an oxidized product of the precursor ergot alkaloid festuclavine. Due to the discovery of
an ergot alkaloid synthesis gene, cloA, catalyzing multiple oxidations on a similar substrate, it was
hypothesized that expression of C. gigantea cloA in a festuclavine-accumulating mutant of the
model fungus Neosartorya fumigata would yield dihydrolysergol. HPLC and LC-MS analyses of
the cloA transformed strains, demonstrated that the modified strain produced dihydrolysergic acid,
the fully oxidized product of dihydrolysergol. Since dihydrolysergol was expected to be the
pathway end product of C. gigantea, the genomic sequence data was analyzed and extracts of fieldgrown C. gigantea. The natural alkaloid analysis results supported the finding that dihydrolysergic
acid is the end product of the C. gigantea pathway, rather than dihydrolysergol. C. gigantea is the
first organism demonstrated to produce the pharmaceutically important compound dihydrolysergic
acid as its pathway end product and heterologous expression of its cloA gene may serve as the
basis of a more efficient approach to production of DHLA for pharmaceutical purposes.
Additional attempts to increase the yield of dihydrolysergic acid in our modified strain, such as
removal of introns, expression from an alternative promoter, and coexpression with an additional
ergot alkaloid synthesis gene, easA, were conducted. The removal of introns and the alternative
promoter had no significant effect on the yield of dihydrolysergic acid compared to the original
cloA transformants in ANOVA (p = 0.58 and p = 0.76). However, the mutants expressing cloAeasA had conversion rates two-fold higher than the mutants expressing cloA (p = 0.01). The data
illustrate that CloA of C. gigantea catalyzes a six-electron oxidation of festuclavine to
dihydrolysergic acid.
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Literature Review/Introduction
Ergot Alkaloids
Ergot is a fungal infection caused by Claviceps species that affect rye, wheat, corn, and
several other monocot plants. Ergot alkaloids are agriculturally and pharmaceutically important,
though many Claviceps species produce ergot alkaloids, which have caused mass poisonings,
called ergotism, as a result of accumulations of these alkaloids in grain crops. Ergot alkaloids also
have caused reduced weight gain and fitness in grazing animals as a result of their accumulation
in related endophytic fungi (Epichloë species) that colonize forage grasses (Robinson and
Panaccione, 2014). However, in 1918, Sandoz marketed ergot alkaloids as bulk pharmaceutical
chemicals, when it was discovered they had clinical uses (Schiff, 2006). Many fungi in the genus
Claviceps (in the family Clavicipitaceae) produce a variety of ergot alkaloids, including clavines
and lysergic acid derivatives. A different set of ergot alkaloids are produced by the distantly related
fungus Neosartorya fumigata, from the family Trichocomaceae. Over 80 distinct types of ergot
alkaloids have been isolated, mainly from the genus Claviceps (Schiff, 2006).
Ergot alkaloids are a family of secondary metabolites and represent the largest group of
nitrogenous fungal metabolites in nature (Schiff, 2006). Ergot alkaloids are limited to a narrow set
of species, such as those found in the families Clavicipitaceae and Trichocomaceae, so they have
a limited distribution in nature. Ergot alkaloids play a role in plant defense, because they have
harmful effects on vertebrate and invertebrate herbivores (Panaccione et al., 2006; Potter et al.,
2008).
Ergot alkaloids are small molecules that are heavily derivatized from the amino acid
tryptophan. Tryptophan is an indole derivative and is a precursor to the neurotransmitter serotonin.
Ergot alkaloids also have structural similarities to the neurotransmitters dopamine, adrenaline, and
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noradrenaline, making them useful pharmaceuticals. Ergot alkaloids’ pharmaceutical effects are
the result of their agonism or antagonism at serotonergic, dopaminergic, and adrenergic receptors
in the central nervous system, as well as at adrenergic receptors in blood vessels (Schiff, 2006;
Gerhards et al., 2014). This allows ergot alkaloids to be used clinically to treat several neurological
and cognitive diseases, such as migraines, dementia, Alzheimer’s, and Hyperprolactinemia
(Morren and Galvez-Jimenez, 2010; Baskys and Hou, 2007; Winblad et al., 2007; Kerr et al., 2010;
Table 1). Several important pharmaceuticals are semisynthetic derivatives of dihydrolysergic acid
or its intermediate dihydroelymoclavine (i.e. dihydrolysergol), which are ergot alkaloids rarely
encountered in nature; therefore elucidating their biosynthetic route would be beneficial (Bilovol
and Panaccione, 2016; Fig. 1; Table 1).

Figure 1: Structures of the dihydroergot alkaloids dihydrolysergol and dihydrolysergic acid compared to
their potential pharmaceutical products. Green arrows indicate the pharmaceuticals dihydrolysergol is
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capable of producing and blue arrows indicate the pharmaceuticals dihydrolysergic acid is capable of
producing.

Table 1: Ergot Alkaloids and their Pharmaceutical Uses
Ergot
Alkaloid

Brand
Name

Clinical use(s)

Current
Efficient
semisynthetic
semisynthetic
derivation
derivation
Nicergoline
Sermion
Senile
dementia, From LA via other From DHlysergol,
Alzheimer’s,
ergot alkaloids
lysergol, or DHLA
cerebral thrombosis
Cabergoline Caberlin,
Hyperprolactinemia From LA via other From DHLA
Dostinex
,
pituitary ergot alkaloids
prolactinomas
Pergolide
Permax
Parkinson’s
From LA via other From DHlysergol
(elsewhere,
ergot alkaloids
withdrawn in USA,
2007)
Ergoloid
Hydergine Senile dementia
From ergopeptines or From
mesylates
LA via other ergot DHergopeptines or
alkaloids
DHLA
DHergotami DHE 45, Migraines
From ergotamine or From DHergotamine
ne
Migranal
LA via other ergot or DHLA
alkaloids
Abbreviation: LA- lysergic acid, DH – dihydro, DHLA – dihyrdrolysergic acid
Ergot Alkaloid Pathway
Individual species in two major fungal families, Clavicipitaceae and Trichocomaceae, are
known to produce ergot alkaloids. All fungi that produce ergot alkaloids share the same early
biosynthetic steps that lead to the formation of the ergoline ring structure, before diverging into
specific ergot alkaloid lineages (Coyle et al., 2014). For the production of all ergot alkaloids, the
ergot alkaloid synthesis (eas) genes that are involved are all found in clusters in each genome of
the producing organism. No gene that is critical to the production of ergot alkaloids is located
outside of an eas gene cluster (Bilovol and Panaccione, 2016). Modifications to the ergoline rings
by enzymes in the eas gene cluster results in chemical products that are used as the basis for
pharmaceutical drugs. Gene clusters from several fungi have been elucidated through genome
mining, knock-out experiments, and overexpression experiments (Gerhards et al., 2014).
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The ergot alkaloid pathway in both Claviceps species and N. fumigata is initiated by the
prenylation of tryptophan, which is catalyzed by dimethylallyltryptophan synthase encoded by the
gene dmaW (Fig. 2). Coyle et al. (2010) demonstrated that chanoclavine-I-aldehyde is the last
shared intermediate in the ergot alkaloid pathway for Claviceps and N. fumigata (Fig. 2). The
branch point between these pathways occurs during the D ring closure, as a result of the products
of different alleles of easA have functional differences. EasA is an oxidoreductase of the ‘old
yellow enzyme’ class, which reduces double bonds that are conjugated to either aldehydes or
ketones. In the ergot alkaloid pathway, EasA reduces the double bond conjugated to the aldehyde
group of chanoclavine-I-aldehyde, which allows for ring closure by Schiff base formation (Coyle
et al., 2010). In N. fumigata, the 8,9 double bond in chanoclavine-I-aldehyde is reduced by the
reductase form of EasA (Fig. 2). The derived iminium ion is further reduced by EasG to form
festuclavine, which can be acetylated at carbon 2 and/or prenylated at carbon 9 to produce
fumigaclavine derivatives (Fig. 2) (Wallwey et al., 2010; Cheng et al., 2010). In most Claviceps
species, an isomerase form of EasA transiently reduces chanoclavine-I-aldehyde before reoxidizing it to produce the 8,9 unsaturated agroclavine (Fig. 2) (Coyle et al., 2010). In C. purpurea
and Epichloë species agroclavine is oxidized to produce elymoclavine, elymoclavine is further
oxidized and isomerized to produce lysergic acid, and lysergic acid is assimilated into ergopeptines
and/or lysergic acid amides (Fig. 2) (Robinson and Panaccione, 2014). As a result of this major
difference, fungi in the family Clavicipitaceae synthesize lysergic acid derivatives, in which
carbons 9 and 10 in the D ring of the ergoline ring structure are unsaturated and carbon 17 is
oxidized (Fig. 2) (Panaccione et al., 2014; Schardl et al., 2006; Lorenz et al., 2009). Fungi in the
family Trichocomaceae synthesize clavine derivatives, in which carbons 9 and 10 in the D ring are
fully saturated and carbon 17 remains as a methyl group (Fig. 2) (Panaccione et al., 2012; Wallwey
and Li, 2011). Lysergic acid derivatives are produced exclusively by the family Clavicipitaceae
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and not by model organisms, like N. fumigata, in which their modification might be facilitated
(Robinson and Panaccione 2014).
Coyle et al. (2010) also created two mutant strains of N. fumigata. The first was an easA
knockout strain, which was created by integrating pAFOYE1, along with the hygromycin
resistance plasmid pMOcosX, into easA (reductase) in order to disrupt its function. The disruption
construct, pAFOYE1, contained a 595 bp fragment from the 1,131 bp coding sequence of easA
from N. fumigata ligated into the T/A overlap vector pCR2.1. This mutant strains pathway ended
at chanoclavine-I-aldehyde, which is the last common intermediate between the fumigaclavine C
and lysergic acid pathways. This strain was also beneficial, because it allowed Coyle et al. (2010)
to investigate the functions of easA isomerase compared to easA reductase. By cotransforming
easA isomerase from C. purpurea along with pBC-phleo, a phleomycin resistance plasmid, into
the easA KO strain, they were able to modify the ergot alkaloid profile. Instead of detecting the
usual alkaloids such as festuclavine and fumigaclavines A,B, and C, they detected setoclavine,
isosetoclavine, and large amounts of agroclavine (Coyle et al. 2010).
Robinson and Panaccione (2014) engineered a strain of N. fumigata to transform
agroclavine into lysergic acid (Fig. 2). This was done by using an N. fumigata easA knockout strain
as host fungus, so that the pathway stopped at chanoclavine-I-aldehyde. A construct containing
easA (isomerase) and a second gene, cloA, both from an Epichloë species, was transformed into
the N. fumigata easA knockout strain, so that the EasA isomerase converted chanoclavine-Ialdehyde into agroclavine and CloA converted agroclavine into lysergic acid. The gene cloA,
which stands for clavine oxidase, was required for complete oxidation of carbon 17 of both
agroclavine and elymoclavine during the synthesis of lysergic acid (Fig. 2). The gene encodes a
P450 monooxygenase and is only found in fungi that produce lysergic-acid derivatives (Robinson
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and Panaccione, 2014). It was concluded that CloA catalyzes a six-electron oxidation of
agroclavine to lysergic acid and that either CloA or EasA isomerizes the 8,9 double bond in the D
ring to the 9,10 position. CloA had multiple catalytic activities, including a two-electron oxidation
of agroclavine to elymoclavine and an additional two sets of two-electron oxidations to convert
elymoclavine to lysergic acid. The lack of detectable elymoclavine in the extracts of the developed
strain indicated that CloA could execute successive oxidations and an isomerization without
releasing the substrate (Robinson and Panaccione, 2014).
Two species from Clavicipitaceae, Claviceps gigantea and Claviceps africana, have been
reported to produce dihydroergot alkaloids, however the genes involved in their biosynthetic
pathways have not been investigated. Dihydroergot alkaloids differ from lysergic acid-derived
alkaloids due to carbons 9 and 10 being saturated and carbon 17 being oxidized (Bilovol and
Panaccione, 2016), giving them different, unique pharmaceutical properties. These species are
similar to N. fumigata, due to chanoclavine-I-aldehyde being reduced by EasA reductase to
produce festuclavine. Barrow et al. (1974) investigated the dihydroergot alkaloid pathway through
an approach based on feeding labeled precursors to the fungus Claviceps africana. They showed
that the dihydroergot alkaloid pathway in C. africana and by extension C. gigantea proceeded
from festuclavine to dihydroelymoclavine to dihydrolysergic acid to dihydroergosine (Fig. 2). It
is predicted that festuclavine could be transformed into dihydroelymoclavine then dihydrolysergic
acid by oxidizing carbon 17, analogous to the agroclavine to lysergic acid pathway.
Dihydrolysergic acid derivatives are also solely produced by the family Clavicipitaceae and not
by model organisms, such as N. fumigata, in which their modification may be facilitated (Robinson
and Panaccione, 2014). Many of the genes that are necessary in the biosynthesis of the lysergic
acid-derived ergot alkaloids have been characterized, but the genes that are necessary in the
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synthesis of dihydroergot alkaloids have yet to be studied (Bilovol and Panaccione, 2016). Among
the genes in the eas cluster, cloA is the reasonable candidate to conduct the first oxidation of carbon
17 of festuclavine to produce dihydroelymoclavine, due to the discovery of its catalytic functions
on a similar substrate, agroclavine (Robinson and Panaccione 2014).

Figure 2: Lysergic acid pathway (left; Robinson and Panaccione, 2014), predicted dihydroergot alkaloid
pathway (middle; Barrow et al., 1974), and fumigaclavine pathway (right; Bilovol and Panaccione, 2016).
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Both intermediates and products are shown along with the enzymes responsible (indicated next to arrows).
Double arrows express the omission of one or more intermediates. The ergoline ring structure is shown in
the top right for reference to descriptions in text.

In N. fumigata, festuclavine is transformed into fumigaclavines through the hydroxylation
and acetylation of carbon 2 and/or the prenylation of carbon 9 (Fig. 2). The gene easM encodes
for the festuclavine-hydroxylating enzyme, which hydroxylates festuclavine into fumigaclavine B
(Fig. 2). Bilovol and Panaccione (2016) prepared an easM knockout strain of N. fumigata, so the
ergot alkaloid pathway stops at and accumulates large quantities of festuclavine (30.9
amol/conidium). The strain was derived by replacing part of the easM coding sequence with a
hygromycin resistance gene, in order to disrupt the gene’s function. This development is
beneficial, because festuclavine is the last common intermediate in both the fumigaclavine branch
in N. fumigata and in the dihydroergot alkaloid pathway in certain Claviceps species. This mutant
strain will be useful for studying genes important in the synthesis of dihydroergot alkaloids, since
festuclavine is the precursor to dihydroergot alkaloids (Bilovol and Panaccione 2016). The
candidate gene, cloA, was tested through expression in an N. fumigata easM knockout (easM KO)
strain and an N. fumigata easA knockout (easA KO) strain.
Claviceps gigantea
A new species of Claviceps was described in the 1960s (Fuentes et al. 1964). The fungus
grew on maize and was reported due to the toxic effects it caused when ingested. The fungus is
recognized by the large, soft sclerotia that replace the kernels on maize. Large numbers of
microconidia occur on the sclerotia, and they were isolated to prove they were the etiological agent
(Ullstrup, 1973). The sclerotia produced the typical stipe and stroma of other Claviceps species,
however, they were much larger than any other described species, so the new species Claviceps
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gigantea was described. C. gigantea has a very limited geographical distribution and is only found
at high altitudes in Mexico, where the climate is cool and humid (Ullstrup, 1973).
C. gigantea was studied for ergot alkaloids in Agurell and Ramstad’s work in 1965.
Festuclavine and dihydroelymoclavine (synonym dihydrolysergol) were two alkaloids isolated
from the sclerotia of the fungus. This was the first time dihydrolysergol was isolated from a natural
source, and it is relevant because dihydrolysergol is closely related to dihydrolysergic acid. For
example, it had previously been chemically cleaved from dihydrolysergic acid methyl ester
(Agurell and Ramstad, 1965). Overall, most species of Claviceps produce derivatives of lysergic
acid. However, it is believed that C. gigantea is capable of producing other dihydroergot alkaloids,
based on the isolation of dihydrolysergol from the fungus. This fungus may be an appropriate
genetic resource for studies on dihydroergot alkaloid biosynthesis.
Rationale and Hypothesis
Though many steps in the ergot alkaloid pathways have been clarified, the dihydroergot
alkaloid pathway remains to be elucidated. As a result, dihydroelymoclavine and dihydrolysergic
acid used for pharmaceutical purposes must be chemically modified from more complex, naturally
occurring ergot alkaloids. The easM knockout strain of N. fumigata created by Bilovol and
Panaccione (2016) is the ideal host for my planned experiment, since it accumulates high amounts
of festuclavine, which is the precursor to dihydroergot alkaloids (Barrow et al., 1974).
Additionally, the discovery of the multiple catalytic functions of the enzyme CloA make it a
reasonable candidate to oxidize carbon 17 of festuclavine to transform it into dihydroelymoclavine
or dihydrolysergic acid. I intend to test the gene cloA from the fungus C. gigantea, due to this
fungus being reported to produce dihydroelymoclavine. Therefore, it is hypothesized that cloA
from C. gigantea introduced into the easM knockout strain of N. fumigata will result in the
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oxidation of festuclavine into dihydroelymoclavine or perhaps dihydrolysergic acid (Fig. 2). The
objective of this project is to modify a strain of N. fumigata to produce dihydroelymoclavine or
dihydrolysergic acid as its final product. This was done by transforming the gene cloA from C.
gigantea into the festuclavine-accumulating easM knockout strain of N. fumigata.
Materials and Methods
C. gigantea gene cluster
The C. gigantea eas gene cluster (Figure 9B) was identified by querying the genome’s
sequence with individual eas genes from other Claviceps species. Additional eas genes were
identified by blastx comparisons to the nonredundant nucleotide database at NCBI.
C. gigantea natural alkaloid analysis
C. gigantea sclerotia samples were obtained from Montecillo, Mexico (Fig. 3). The head
of the sclerotia was pulverized with 10 glass beads (3-mm diameter) in 300 µL of HPLC-grade
methanol by a Fastprep 120 (Bio101, Carlsbad, CA) for 30s at 6 m/s. Alkaloids were extracted for
1 hour, then the sample was pelleted by centrifugation and 20 µL of supernatant was analyzed by
HPLC with fluorescence detection.
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Figure 3: Image of three C. gigantea sclerotia samples analyzed for natural alkaloid production. The top
row are the sclerotia heads, which were analyzed for alkaloid production, and the bottom row are the
corresponding sclerotia tails.

Resequencing of pseudogene lpsA from C. gigantea
Part of the pseudogene lpsA was amplified from C. gigantea genomic DNA using primer
combination 14 (Table 2) using Phusion high-fidelity polymerase (Thermo Fisher, Waltham, MA).
The fragment contained 743 bp corresponding to nucleotides 3997 to 4739 in the lpsA coding
sequence and contained the suspected frameshift mutation (GenBank: KY906251). Phusion
polymerase creates products with blunt ends, so the amplified product was purified (Qiagen) and
ligated into SmaI-digested pUC18. This construct was then transformed into Escherichia coli,
plasmid prepped (Qiagen), and sequenced to confirm frameshift mutation found during the
characterization of C. gigantea’s eas gene cluster (Eurofins, Louisville, KY).
Preparation of transformation constructs
Four different constructs were prepared in attempts to accumulate and increase the yield of
dihydrolysergic acid (Fig. 5). The first construct contained cloA from C. gigantea and a
bidirectional easA-easG promoter from N. fumigata (Fig. 4, Fig. 5A). The second construct
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contained an intron free version of cloA from C. gigantea and the bidirectional easA-easG
promoter from N. fumigata (Fig. 4, Fig. 5B). The third construct contained an intron free version
of cloA from C. gigantea and a strong gpdA promoter from N. fumigata (Fig. 4, Fig. 5C). The
fourth construct contained an intron free version of cloA from C. gigantea, the bidirectional easAeasG promoter from N. fumigata, and easA from C. gigantea (Fig. 4, Fig. 5D). All of the PCR
amplifications used Phusion high-fidelity polymerase (Thermo Fisher, Waltham, MA) and
followed the same protocol, with an initial denaturation at 98°C for 30s, followed by 35 cycles of
98°C (15 s), AT°C (15 s), and 72°C (ET s), and a final extension at 72°C for 60s (AT=annealing
temperature, ET=extension time, Table 2). The 25 µL PCR mixture contained 11 µL
distilled/deionized water, 5 µL 5x buffer (100 mM KCl, 20 mM Tris-HCl pH 7.4, 1.5 mM MgCl2),
4 µL dNTPs (final concentration 200 µM each), 1.25 µL forward primer (final concentration 0.5
µM), 1.25 µL reverse primer (final concentration 0.5 µM), 2 µL DNA template, and 0.5 units of
Phusion high-fidelity polymerase. All PCR products were run on agarose gels (0.8% wt/vol) in 0.5
x TBE (45 mM Tris-Borate, 1 mM EDTA) with ethidium bromide (500 ng/mL).
C. gigantea cloA construct
To test whether CloA from C. gigantea would catalyze oxidation of festuclavine, an
easA/easG promoter-cloA construct was prepared (Fig. 5A), for expression of cloA, in a
festuclavine-accumulating easM knockout strain of N. fumigata. Primer combination 1 was used
for amplification of cloA from C. gigantea genomic DNA (Tooley et al., 2006) by PCR (Fig. 4,
Table 2). The reverse primer in the combination was assembled with an oligonucleotide that
contained a HindIII restriction site (AAGCTT) near its 5’ end to facilitate cloning of the product
(Fig. 5A). Primer combination 2 was used for PCR amplification of the easA-easG promoter from
N. fumigata wild type strain Af293 (Fig. 4, Table 2). The forward primer in the combination was
assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5’
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end (Fig. 5A). The two fragments were joined by adding equimolar amounts of the two initial PCR
products into a fusion PCR, using primer combination 3 (Fig. 4, Table 2) to form a construct for
expressing C. gigantea cloA in N. fumigata (Fig. 5A). The easA/easG promoter-cloA construct was
double-digested with HindIII and XbaI, then ligated into HindIII/XbaI-digested pBC-phleo
(Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin resistance
after fungal transformation (Fig. 5A). The plasmid was transformed into E. coli, plasmid prepped
(Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and DNA
sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed by
established methods (Robinson and Panaccione, 2014) into the festuclavine-accumulating easM
knockout strain of N. fumigata.
C. gigantea intron free cloA construct
To test whether an intron free version CloA from C. gigantea would better convert
festuclavine to dihydrolysergic acid, an easA/easG promoter- intron free cloA construct was
prepared (Fig. 5B) for expression in the same N. fumigata easM knockout strain. Primer
combination 4 was used to amplify an intron version of cloA with easA-easG promoter and 3’UTR
extensions from the 1,524 bp cDNA (see mRNA analysis) (Fig. 4, Table 2). Due to the cDNA not
having the cloA 3’ UTR, a cloA 3’UTR segment with cloA extension was also individually
amplified from C. gigantea DNA using primer combination 5 (Fig. 4, Table 2). The reverse primer
in the combination was assembled with an oligonucleotide that contained an EcoRI restriction site
(GAATTC) near its 5’ end to facilitate cloning of the product (Fig. 5B). The 5’ UTR was included
in the bidirectional easA/easG promoter, so it did not need individually amplified. Primer
combination 2 was used for PCR amplification of the easA-easG promoter with cloA extension
from N. fumigata wild type strain Af293 (Fig. 4, Table 2). The forward primer in the combination
was assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its
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5’ end (Fig. 5B). The three fragments were joined by adding equimolar amounts into a fusion PCR,
using primer combination 6 (Fig. 4, Table 2) to form a construct for expressing a fully processed
version of cloA from C. gigantea in N. fumigata (Fig. 5B). The easA/easG promoter-intron free
cloA construct was double-digested with EcoRI and XbaI, then ligated into EcoRI/XbaI-digested
pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin
resistance after fungal transformation (Fig. 5B). The plasmid was transformed into E. coli, plasmid
prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and
DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed with
the same methods, into the festuclavine-accumulating easM KO.
C. gigantea gpdA promoter construct
To test whether a stronger promoter from N. fumigata would increase expression of cloA
in attempts to increase conversion of festuclavine to dihydrolysergic acid, a gpdA promoter- intron
free cloA construct was prepared (Fig. 5C) for expression in the N. fumigata easM knockout strain.
Primer combination 7 was used to amplify an intron-free version of cloA with gpdA promoter and
3’UTR extensions from the 1,524 bp cDNA (see mRNA analysis) (Fig. 4, Table 2). Primer
combination 8 was used for PCR amplification of the gpdA promoter with cloA extension from N.
fumigata wild type strain Af293 (Fig. 4, Table 2). No restriction site needed to be assembled to the
primer, because the sequence already contained an XbaI restriction site (TCTAGA) near its 5’ end
(Fig. 5C). Equimolar amounts intron-free cloA, gpdA promoter, and 3’UTR (from the previous
section) were combined in a fusion PCR, using primer combination 9 (Fig. 4, Table 2) to form a
construct for analyzing the effect of a new, stronger promoter (Fig. 5C). The gpdA promoter-intron
free cloA construct was double-digested with EcoRI and XbaI, then ligated into EcoRI/XbaIdigested pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for
phleomycin resistance after fungal transformation (Fig. 5C). The plasmid was transformed into E.
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coli, plasmid prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic
digests and DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then
transformed with the same methods, into the festuclavine-accumulating easM KO strain.
C. gigantea easA-cloA construct
To test whether CloA required a species specific EasA to function properly, an easAeasA/easG promoter- intron free cloA construct was prepared (Fig. 5D) for expression in an N.
fumigata easA knockout strain. The bidirectional promoter had to be reamplified using primer
combination 10, in order to add on easA and cloA extensions (Fig. 4, Table 2). The easA segment
with bidirectional promoter extension was amplified from C. gigantea DNA using primer
combination 11 (Fig. 4, Table 2). The forward primer in the combination was assembled with an
oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5’ end to facilitate
cloning of the product (Fig. 5D). The construct was assembled by adding equimolar amounts easA,
bidirectional promoter, cloA, and 3’UTR into a fusion PCR, using primer combination 12 (Fig. 4,
Table 2). The reverse primer for the fusion product was assembled with an oligonucleotide that
contained a HindIII restriction site (AAGCTT), due to easA from C. gigantea already having an
EcoRI site in its sequence (Fig. 5D). The easA-cloA construct was double-digested with HindIII
and XbaI, then ligated into HindIII/XbaI-digested pBC-phleo (Fungal Genetics Stock Center,
Manhattan, KS) to allow for selection for phleomycin resistance after fungal transformation (Fig.
5D). The plasmid was transformed into E. coli, plasmid prepped (Qiagen, Gaithersburg, MD), and
the construct was confirmed by enzymatic digests and DNA sequencing (Eurofins, Louisville,
KY). The confirmed plasmid was then transformed with the same methods, into an easA KO N.
fumigata strain.
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Figure 4: PCR images resulting from the primer combinations in Table 1. Arrows indicate fragments of
different lengths. Sizes of relevant fragments of BstEII-digested bacteriophage λ DNA is indicated to the
left of the image. If = intron free.

Figure 5: A) pBC-phleo vector containing the bidirectional easA/easG promoter-cloA construct (Construct
1). B) pBC-phleo vector containing the bidirectional easA/easG promoter-intron free cloA-3’UTR construct
(Construct 2). C) pBC-phleo vector containing the gpd promoter-intron free cloA-3’UTR construct. D)
pBC-phleo vector containing the easA-bidirectional easA/easG promoter-intron free cloA-3’UTR construct.
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Table 2: Primers and PCR Protocol Information

Primer Combination
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Primer Sequences
GAGTAGGCACTCCGCACCATGTCACTAACATCGTTTTACGCCC +
CTACAAGCTTCGACTAGGCCACCCACACC
GACCTCTAGACATTGCTTCTAATCCACCAAGTACTTG +
GGCGTAAAACGATGTTAGTGACATGGTGCGGAGTGCCTACTC
GACCTCTAGACATTGCTTCTAATCCACCAAGTACTTG +
CTACAAGCTTCGACTAGGCCACCCACACC
GAGTAGGCACTCCGCACCATGTCACTAACATCGTTTTACGCCC +
CCGCCGATGTCATACTTCAACTAGTATGTGACTTCAGTCCATC
GACTGAAGTCACATACTAGTTGAAGTATGACATCGGCG +
CACAGAATTCGAACTTCTGTGACGTCGCCAGATTG
GACCTCTAGACATTGCTTCTAATCCACCAAGTACTTG +
CACAGAATTCGAACTTCTGTGACGTCGCCAGATTG
GTACCAGACGAATCTACACAATGTCACTAACATCGTTTTACGCC +
CCGCCGATGTCATACTTCAACTAGTATGTGACTTCAGTCCATC
GATTCTAGAAGTCCTGAATAGTAG +
GGCGTAAAACGATGTTAGTGACATTGTGTAGATTCGTCTGGTAC
GATTCTAGAAGTCCTGAATAGTAG +
CACAGAATTCGAACTTCTGTGACGTCGCCAGATTG
GAGTTTGGACGTGGACATTGCTTCTAATCCACCAAGTAC +
GGCGTAAAACGATGTTAGTGACATGGTGCGGAGTGCCTACTC
GACATCTAGACTGGCGACGTCACAGAAGTTC +
GGTGGATTAGAAGCAATGTCCACGTCCAAACTCTTCAAC
GACATCTAGACTGGCGACGTCACAGAAGTTC +
CACAAAGCTTGAACTTCTGTGACGTCGCCAGATTG
CTATAGAGTAGGCACTCCGCAC + CTACGCCGACTACTGTTGTCC
CAGTTCGAGCACGTCTTCTCG + GTGCTCGACAATCATGAGGTC

Product
cloA with bidirectional promoter
extension
Bidirectional promoter with cloA
extension
Bidirectional promoter-cloA
fusion construct
IF cloA with bidirectional
promoter and 3' UTR extensions

Annealing
Length (bp) Temperature (°C) Extension Time (s)
2491

63

75

814

64

30

3253

63

100

1562

63

40

63

20

64

90

61

40

64

40

60

90

64

30

63

60

63
58
60

180
45
30

3' UTR + cloA extension
422
Bidirectional promoter-cloA -3'
UTR fusion construct
2713
IF cloA with gpd promoter and 3'
UTR extensions
1564
gpd promoter with cloA
extension
990
gpd promoter-cloA -3'UTR fusion
construct
2889
Bidirectional promoter with cloA
and easA extensions
835
easA with bidirectional promoter
extension
1322
easA -bidirectional promoter-cloA3'UTR fusion construct
4054
cloA internal sequences (cDNA) 1524 -1621
lpsA internal sequences
743

Fungal Transformation
The easA/easG promoter-cloA construct, the easA/easG promoter- intron free cloA
construct, and the gpdA promoter- intron free cloA construct were transformed into an N. fumigata
easM KO strain, and the easA- easA/easG promoter- intron free cloA construct was transformed
into an N. fumigata easA KO strain. All constructs were transformed with a phleomycin resistance
vector containing the gene, ble, from Aspergillus niger.
Protoplasts were prepared by growing fungal cultures in 50 mL of malt broth at 37 °C with
shaking at 80 rpm overnight. The broth was discarded and replaced with 15 mL 0.7 M NaCl
containing 40 mg lysing enzyme (Sigma-Aldrich, St. Louis, MO) and 1 g VinoTaste Pro (Gusmer
Enterprises Inc., Mountainside, NJ), then shaken for an additional 2 hours at 37 °C and 80 rpm.
Protoplasts were separated from hyphae by filtering through miracloth and then were pelleted by
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centrifugation (3 min at 3,000 × rpm). The protoplasts were washed with 10 mL 0.7 M NaCl and
5 mL STC (1 M Sorbitol, 1 M Tris (pH = 7.4), 1 M CaCl2), and then resuspended in a final volume
of STC, so that a 100 µL would have 5x106 protoplasts. A polyethylene glycol (PEG) solution was
prepared by adding 2 volumes of 37.5% PEG 8000 to 1 volume of PEG amendments (1.8 M KCl,
150 mM CaCl2, 150 mM Tris (pH = 7.47)) and was added to the protoplast solution in the amount
of ¼ the final volume that the protoplasts are in. Once the final protoplast solution was prepared,
125 µL was added to 10 µL of the desired plasmid and incubated on ice for 30 minutes. An
additional 1 mL of PEG solution was added to the solution and incubated at room temperature for
20 minutes. The solution was then split across 3 petri dishes (about 365 µL each) and mixed with
15 mL molten TM102 media (Rykard et al., 1982). Once solidified, an additional layer of molten
TM102 mixed with 800 µg/mL phleomycin (InvivoGen, San Diego, CA) was added. The plates
were incubated for 3 days at 37 °C and the blue fungal colonies were replated on malt extract agar
plates and analyzed by HPLC with fluorescent detection.
mRNA analysis
Transformed fungal cultures were grown in 50 mL of malt extract broth in a 250-mL
Erlenmeyer flask for 1 day at 37°C with shaking at 80 rpm. The produced fungal mat was placed
in a petri dish and incubated at 37°C for an additional day. The RNeasy Plant Mini kit (Qiagen,
Gaithersburg, MD) was used to extract RNA from approximately 80 mg of fungal mat. RNA was
treated with DNaseI (RNeasy Mini kit) in place of step 6 of the protocol and was reverse
transcribed with Superscript IV (bypassing the optional RNAse H step). Resulting cDNA was
diluted 1:10 and amplified by PCR using Phusion high-fidelity DNA polymerase and primer
combination 13 (Table 2) to test for the presence of cloA. The resulting gel showed two bands, so
the PCR product was reloaded onto a 0.8% agarose gel and run at 25 V for 4 hours to effectively
separate these bands, for easier individual purification with Qiaquick columns. Both purified
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versions of cDNA were ligated into SmaI-digested pUC18 and transformed into E. coli (Fig. 10B),
in order to have higher concentrations for sequencing, and the resulting plasmids were sent for
sequencing (Eurofins, Louisville KY).
Agroclavine feeding study
The ability of cloA from C. gigantea to utilize both festuclavine and agroclavine as
precursors was tested by feeding agroclavine to a C. gigantea cloA-bidirectional easA/easG
promoter transformed N. fumigata strain. Agroclavine is oxidized to lysergic acid by cloA from
Epichloë sp. Lp1. Twelve cultures of the transformed strain and N. fumigata easM KO strain were
grown from 60,000 conidia in 200 µL of malt broth. Six cultures of each were supplemented with
2 µL of agroclavine (10 nmol/µL in 2 µL methanol), whereas the other six cultures were
supplemented with 2 µL of methanol as a control. Twelve malt extract broth controls were also
treated with the same supplements. The cultures grew for 1 week in a 37°C incubator. After
incubation, the cultures were extracted by pulverization with 300 µL HPLC-grade methanol and
10 glass beads (3-mm-diameter) in a Fastprep 120 (Bio101, Carlsbad, CA) for 30s at 6 m/s. The
extracted alkaloids were analyzed by HPLC with fluorescence detection for the presence of
lysergic acid.
Compartmentalization study
In order to test whether the substrate and enzymes were being localized in different
compartments, a compartmentalization study was conducted. Transformed N. fumigata cultures
were grown in 50 mL of malt extract broth in a 250-mL Erlenmeyer flask for 2 days at 37 °C with
shaking at 80 rpm for sufficient sporulation. The resulting fungal mat was divided into equal thirds.
Two of the thirds were homogenized with 200 µL 0.1 M phosphate buffer (pH = 7.6; Kim et al.,
1981), and 0.1 M phosphate buffer supplemented with NADPH (7.5 mg/mL), respectively. The
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homogenized solutions were transferred to 2-mL microcentrifuge tubes, supplemented with 150
µL 0.06% Tween 20, and incubated for 2 hours at 23°C. After incubation, equal parts of HPLCgrade methanol were added to each solution, pelleted by centrifugation, and 90 µL were analyzed
by HPLC with fluorescence detection. The remaining third was analyzed for ergot alkaloids as the
control.
HPLC and LC-MS analyses of the transformants
Colonies from each transformant were grown on malt agar for 3-5 days. Samples were
taken with the wide end of a 1,000 µL pipette tip and alkaloids were extracted with 300 µL HPLCgrade methanol at 23°C for 1 hour. The extracts were pelleted by centrifugation and 20 µL were
analyzed by reverse-phase high-performance liquid chromatography (HPLC) with fluorescent
detection. All samples were separated with a multilinear binary gradient of 5% acetonitrile in
50mM ammonium acetate to 75% acetonitrile in 50 mM ammonium acetate on a 150-mm by 4.6mm C18 column (Phenomenex Prodigy ODS3, 5µm particle size; Torrance, CA; Panaccione et
al., 2012). A dihydrolysergic acid standard was prepared by dissolving 1 mg ergoloid mesylate
(Sigma) in 100 µL of 1.2 M NaOH at 75°C for 6 hours, succeeded by the addition of 1.2 M HCl
to neutralize the standard.
Festuclavine and dihydrolysergic acid were quantified from all three transformed strains
derived from easM KO. Festuclavine, dihydrolysergic acid, and fumigaclavine C were quantified
from the transformed strain derived from easA KO. Agroclavine, lysergic acid, and isolysergic
acid were quantified from agroclavine fed cultures. All alkaloids were quantified by comparing
their peak areas to standard curves prepared from dihydroergocristine (for alkaloids fluorescing at
272 and 372 nm) and ergotamine (for alkaloids fluorescing at 310 and 410 nm). The percent of
festuclavine converted into dihydrolysergic acid and the percent of agroclavine converted to
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lysergic acid were calculated and compared by analysis of variance (ANOVA). Statistical analyses
were conducted with JMP (SAS, Cary, NC).
For liquid chromatography-mass spectrometry (LC-MS) analysis, week old cultures grown
on malt extract agar were washed with 4 mL of HPLC-grade methanol. The samples were pelleted
by centrifugation, concentrated for 4-5 hours in a vacuum centrifuge to a volume between 50-100
µL, and 10 µL were injected into the LC-MS. The concentrated samples were analyzed by previous
methods (Ryan et al., 2013) on a Thermo Fisher LCQ DecaXP LC-MS. Dihydrolysergic acid
samples were analyzed on a Thermo Fisher Q Exactive ultrahigh-performance liquid
chromatograph mass spectrometer (UHPLC-MS). Analytes were ionized by electrospray
ionization in positive mode, a spray voltage of 3.5 kV, a capillary temperature of 300°C, and were
detected by scanning for ions with m/z 200-400. Samples were separated on a 50-mm by 2.1-mm
Hypersil Gold column (Thermo Fisher, 1.9 µm particle size) in a linear gradient of 5% acetonitrile
with 0.1% formic acid to 75% acetonitrile with 0.1% formic acid over a 10 minute period with a
flow rate of 300 µL/min (Ryan et al., 2013). Dihydrolysergic acid has an m/z = 271.2 and was
eluted at about 7.8 minutes. After an initial full scan of m/z = 200-400, ions of m/z = 271.2 were
fragmented and analyzed.
Results
Function of C. gigantea cloA. A construct for expressing C. gigantea cloA was successfully
transformed into the N. fumigata easM KO strain. A total of 52 transformants were obtained
from several transformation experiments, and 33 produced a novel peak that co-eluted with
dihydrolysergic acid as evidenced by HPLC with fluorescence detection (Fig. 6). No other novel
peaks of significance were observed in the transformants, but relatively large quantities of
festuclavine were still observed. The recipient strain, N. fumigata easM KO, accumulated large
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quantities of festuclavine (data not shown) and nothing that eluted near dihydrolysergic acid
(Fig. 6) The accumulation of dihydrolysergic acid in the transformants was supported by LC-MS
analyses in which the cloA-transformed strains produced a parent ion (m/z = 271.2) consistent
with the [M+H]+ of dihydrolysergic acid (data not shown). The data indicate that CloA catalyzes
a six-electron oxidation of festuclavine to dihydrolysergic acid as opposed to stopping at
dihydroelymoclavine (Fig. 2) as expected based on the reported ergot alkaloid profile of C.
gigantea (Agurell and Ramstad, 1965). The accumulation of dihydrolysergic acid, however, was
low in comparison to the abundance of festuclavine in the transformed strains. Potential reasons
for this low accumulation, as well as attempts to increase the yield of dihydrolysergic acid are
discussed below.

Figure 6: HPLC analysis of transformant strain, dihydrolysergic acid (DHLA) standard, and easM ko host
strain.

Analysis of the natural ergot alkaloid profile of C. gigantea. Due to C. gigantea catalyzing the
production of dihydrolysergic acid instead of dihydroelymoclavine, three samples of C. gigantea
sclerotia (Fig. 3) were obtained from Dr. Carlos De Leon (Monticello, Mexico) and analyzed by
HPLC (Fig. 7) and LC-MS (Fig. 8) for natural alkaloid production to further investigate its ergot
alkaloid biosynthetic capacity. Each of the three sclerotia samples accumulated chanoclavine,
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festuclavine, and dihydrolysergic acid (Fig. 7). This alkaloid profile differed from that reported by
Agurell

and

Ramstad

(1965),

which

included

chanoclavine,

festuclavine,

and

dihydroelymoclavine. Even though a compound with the mass of dihydroelymoclavine was not
detected it is possible the concentration was below the limit of detection. Another possibility is
that ergot alkaloid profile varies among isolates of C. gigantea.

Figure 7: Natural ergot alkaloid HPLC chromatogram for C. gigantea sclerotia. DHLA = dihydrolysergic
acid, C = chanoclavine, F = festuclavine.

Figure 8: LC-MS mass spectra for C. gigantea sclerotia compared to DHLA standard. Top left is the parent
ion (m/z = 271.2) for DHLA in C. gigantea and bottom left is fragment ions (m/z = 253.1, 210.1, 228.1,
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and 194.2) for DHLA in C. gigantea. This data can be compared to the DHLA standard mass spectra, with
the top right being the parent ion and the bottom right being the fragment ions.

Characterization of C. gigantea eas gene cluster. The eas gene cluster in the C. gigantea
genome was characterized to obtain evidence for the type of ergot alkaloids the fungus was
theoretically capable of producing. The eas cluster (GenBank: KY906251) was studied by
identifying contigs that contain eas genes by querying the genome’s sequence (Panaccione and
Schardl, unpublished) with individual eas genes from other Claviceps species. Additional eas
genes were identified in the originally identified contigs by blastx comparisons of upstream and
downstream portions of the contigs to the nonredundant nucleotide database at NCBI. The eas
cluster contained homologs of the following eas genes: dmaW, easF, easC, easE, easD, easA,
easG, cloA, lpsA, lpsB, and easH (Fig. 9B). The gene cluster indicates the fungus was once
capable of producing a dihydroergopeptine derivative of dihydrolysergic acid. This hypothesis
was supported by the observation that the product of the gene cloA from C. gigantea oxidized
carbon 17 of festuclavine to produce dihydrolysergic acid.

Figure 9: A) Ergot alkaloid synthesis (eas) cluster from wild-type Neosartorya fumigata. B) Predicted eas
cluster from Claviceps gigantea. Eas genes found in both clusters are grey, whereas genes exclusive to N.
fumigata are white and genes exclusive to C. gigantea are black. Ψ: pseudogene.

The gene lpsA encodes lysergyl peptide synthetase subunit 1 and acts downstream of CloA
in the pathway to convert dihydrolysergic acid into ergopeptines. Sequencing of lpsA from C.
gigantea along with comparison to other sequenced lpsA alleles revealed a frameshift mutation,
which would almost certainly render the gene nonfunctional. The frameshift is believed to occur
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between 4345 bp and 4352 bp, since the regions upstream and downstream this frameshift match
other sequenced lpsA alleles. This frameshift has a span of 8 nucleotides and there should only be
6 nucleotides in this area to have the correct reading frame. This frameshift mutation results in a
premature termination codon appearing after amino acid 1458 (4374 bp). The original LpsA
product should have been 3581 amino acids in length (encoded by 10743 bp), meaning that more
than half of the coding sequence would not have been translated in the correct reading frame. When
comparing the C. gigantea lpsA sequence data (GenBank: KY906251) to the Periglandula
ipomoeae lpsA sequence data (GenBank: AEV21218.1) the altered amino acids are an alanine and
a valine. The removal of an adenine in the frameshift (located at 4350 bp) in C. gigantea would
reinstate a valine in the correct position. It does not appear any nucleotide removals in the
frameshift will reinstate an alanine. However between 4346 bp and 4348 bp there are three
adenines, making it plausible that one of these nucleotides is the second single nucleotide insertion
causing the frame shift. The removal of one of these adenines would code for glutamic acid and
reinstate the correct reading frame. Such a mutation is consistent with the accumulation of
dihydrolysergic acid as the pathway end product in the C. gigantea sclerotia and it is predicted that
a functional lpsA homolog would accumulate dihydroergopeptines. It should be noted that the C.
gigantea genome was obtained from an isolate independent of those analyzed by LC-MS. This
observation indicates that the dihydrolysergic acid profile is typical among several independent
isolates of C. gigantea from Mexico.
Approaches to increase production of dihydrolysergic acid. In order to check for cloA’s
expression and to see if the introns in cloA were being spliced out correctly, mRNA was extracted
from the transformants, reverse-transcribed into cDNA, and were sequenced. PCR analyses of
cDNA prepared from mRNA from the cloA-transformed strain indicated that approximately half
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of the mRNA was fully processed, whereas the other half was larger than expected (Fig. 10A).
Sequencing results identified two versions of mRNA, the larger being 1,621 and the smaller being
1,524 bp. The larger fragment retained 1 out of the 7 introns, specifically intron 4, and the smaller
fragment was free of introns and likely responsible for the small conversion of dihydrolysergic
acid (Fig. 10 C). However, the retention of intron 4 results in a frame shift that leads to a stretch
of 6 incorrect amino acids, followed by a premature termination codon, causing the loss of 288
amino acids, which presumably renders the resulting protein nonfunctional (Fig. 10D). It was
plausible that cloA mRNA containing intron 4 could be an issue limiting the production of
dihydrolysergic acid in the transformed strain.
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Figure 10: A) cloA cDNA. Arrows indicate fragments of different lengths. Sizes of relevant fragments of
BstEII-digested bacteriophage λ DNA is indicated to the left of photograph. B) pUC18 containing cloA
cDNA. C) Genomic cloA with introns and cloA as expressed in transformants with some mRNA containing
intron 4 (larger band in Fig. 6A) and some with no introns (smaller band in Fig. 6B). D) Amino acid
sequence for cloA and cloA with intron 4 retained. The amino acid sequence after the 5’-splice junction of
intron 4 is highlighted yellow.

In an attempt to increase turnover of festuclavine to dihydrolysergic acid, new versions of
the cloA expression construct were prepared using the fully processed cDNA as the template. This
fully processed version of cloA was expressed by the original N. fumigata easA-easG promoter to
test the effectiveness of removing the intron, and was also expressed by a gpdA promoter to analyze
if a stronger promoter would increase the accumulation of dihydrolysergic acid. Both constructs
were analyzed by HPLC and LC-MS for production of dihydrolysergic acid. HPLC data is shown
for both transformed strains (Fig. 12), LC-MS data is shown for gpdA promoter-cloA transformed
strain to confirm the product is dihydrolysergic acid (Fig. 11). LC-MS data for intron free cloA is
not shown. The conversion yields of festuclavine to dihydrolysergic acid were similar, indicating
the removal of introns (p = 0.58) and a stronger promoter (p = 0.75) did not have a significant
impact on production of dihydrolysergic acid (Table 3). Since gpdA promoter-cloA transformed
strains did not produce larger amounts of dihydrolysergic acid, it did not seem relevant to analyze
the expression of cloA in these transformants.
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Figure 11: LC-MS mass spectra for gpd-if cloA transformed strain compared to LC-MS data for DHLA
standard. Top left shows the parent ion (m/z = 271.2) for transformed strain and bottom left shows fragment
ions (m/z = 253.1, 210.1, 228.1, and 194.2) for transformed strain. These values can be compared to the
DHLA standard, with top right showing parent ion (m/z = 271.2) and bottom right showing fragment ions
(m/z = 253.1, 210.1, 228.1, and 194.2).

In previous studies conducted by Robinson and Panaccione (2014) cloA and easA from
Epichloë sp. Lp1 were cotransformed into an N. fumigata easA knockout strain. The gene easA
(isomerase) converted chanoclavine-I-aldehyde to agroclavine, the precursor for Lp1 cloA in their
study. Since cloA was not transformed individually it was questioned whether CloA requires EasA,
preferentially from the same source, to function optimally. The gene easA from C. gigantea was
PCR fused to the free end of the bidirectional N. fumigata easA-easG promoter in the intron-free
cloA construct. The construct was transformed into an N. fumigata easA KO strain and analyzed
via HPLC (Fig. 12). The addition of easA (isomerase) from C. gigantea converted chanoclavine
to our precursor, festuclavine, which was then oxidized to dihydrolysergic acid by cloA (Fig. 12).
However, the easA KO strain still contained the gene, easM, the product of which converted
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festuclavine into fumigaclavine B, which was ultimately converted to fumigaclavine C via the N.
fumigata fumigaclavine pathway (Fig. 12). Since festuclavine was also being converted to
fumigaclavine C, fumigaclavine C had to be taken into account when calculating the percent
conversion of dihydrolysergic acid. Even with the diversion of some of the substrate to
fumigaclavine C, the yield of dihydrolysergic acid increased with the addition of C. gigantea easA
to the construct (p = 0.01, Table 3).

Figure 12: HPLC analysis of intron free-cloA transformed strain (top), gpd-cloA transformed strain
(middle), and easA-cloA transformed strain (bottom). All three analyses also include dihydrolysergic acid
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standard, easM ko host strain (top and middle), and easA ko host strain (bottom). DHLA = dihydrolysergic
acid, F = festuclavine, C = chanoclavine, Fum C = fumigaclavine C.

Additionally, since it was speculated that CloA was being localized in different subcellular
locations than the festuclavine substrate, the strain containing cloA expressed from the gpd
promoter was homogenized and the resulting solutions were incubated with 0.06% Tween 20, and
either 0.1 M phosphate buffer (pH = 7.6) or 0.1 M phosphate buffer supplemented with NAPDH
(7.5 mg/mL). The homogenized solution was analyzed via HPLC and the quantitative data was
analyzed using ANOVA and Tukey-Kramer HSD (Table 4). The percent conversion to
dihydrolysergic acid was only significantly different between the control and the homogenized
solution incubated with phosphate buffer + NADPH. The other two comparisons were not
significantly different.
Table 3: Amount of dihydrolysergic acid converted from festuclavine
Modified strain
Percent conversion to DHLA
1.6 ± 0.7 A
cloA
2.1 ± 0.5 A
intron-free cloA
1.9 ± 0.5 A
gpd promoter
4.3 ± 1.5 B
easA-cloA
Values labeled with different capital letters differ significantly in ANOVA (p = 0.01). DHLA =
dihydrolysergic acid.
Table 4: Homogenization effect on the production of dihydrolysergic acid
Homogenization Method
Percent conversion to DHLA
Control
2.6 ± 0.4 A
Phosphate Buffer
3.7 ± 0.6 AB
Phosphate Buffer + NADPH
4.6 ± 1.2 B
Values labeled with different capital letters differ significantly in ANOVA and Tukey-Kramer
HSD (p = 0.02). DHLA = dihydrolysergic acid.
Another possible issue that could have been limiting the production of the alkaloid is the
temperature at which the transformants were grown, since C. gigantea is only found in two regions
in Mexico, both having cool, humid climates. This made it plausible that the C. gigantea enzymes
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had a different optimal temperature for activity than N. fumigata. Transformed strains were grown
at 24 °C, 37 °C, and 50 °C and analyzed by HPLC with fluorescent detection. The optimal
temperature for C. gigantea gene expression was 37°C, which is the same optimal temperature for
N. fumigata (Table 5).
Table 5: Temperature Effect on the Production of Dihydrolysergic Acid
Temperature
Percent conversion to dihydrolysergic acid
24 °C
1.8 ± 0.2 A
37 °C
3.6 ± 0.4 B
50 °C
N/A
Values labeled with different capital letters differ significantly in ANOVA (p = 0.003)
Substrate specificity of C. gigantea CloA. In order to test substrate specificity of C. gigantea
CloA, the cloA-transformed strains were fed agroclavine. HPLC analysis showed the agroclavinefed transformants accumulated lysergic acid (15.1) and isolysergic acid (21.2) (Fig. 13, Table 6).
This indicates that CloA from C. gigantea is capable of oxidizing both festuclavine and
agroclavine as substrates.
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Figure 13: HPLC analysis of transformed cloA strain fed agroclavine. Top image is chromatogram at 310
nm/410 nm wavelength and bottom image is chromatogram at 272 nm/372 nm wavelength. LA = lysergic
acid, Iso-LA = isolysergic acid, Iso-S = isosetoclavine, S = setoclavine, Agro= agroclavine.

Table 6: Amount of lysergic acid converted from agroclavine
Modified strain
Percent conversion to LA
cloA + agroclavine
0.93 ± 0.13
easM KO + agroclavine
ND
malt broth + agroclavine
ND
The cloA mutant strain that was fed agroclavine was significantly different from the other trials in
a Wilcoxon/Kruskal-Wallis test with p = 0.003. ND = none detected; LA = lysergic acid.
Discussion
The expression of CloA in an N. fumigata easM knockout strain altered the fungus to
imitate the dihydrolysergic acid pathway. Bilovol and Panaccione (2016) synthesized the easM
KO strain to demonstrate the role of easM in the N. fumigata fumigaclavine pathway. This
transformant also serves as a transformation recipient to investigate the oxidation of festuclavine
to dihydroergot alkaloids, based on Barrow et al.’s (1974) finding that festuclavine was a precursor
to dihydroergot alkaloids in Claviceps africana and by extension Claviceps gigantea. Agurell and
Ramstad (1965) isolated ergot alkaloids from natural C. gigantea, including festuclavine and
dihydroelymoclavine. As a result, it was predicted a C. gigantea cloA-transformed strain of N.
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fumigata would convert festuclavine into dihydroelymoclavine. The mutant strain, however,
produced dihydrolysergic acid rather than dihydroelymoclavine. These data support the findings
of Robinson and Panaccione (2014) of CloA catalyzing multiple oxidations. It appears the C.
gigantea allele of CloA performs a two-electron oxidation of festuclavine to dihydroelymoclavine,
followed by two sets of two-electron oxidations to convert dihydroelymoclavine to dihydrolysergic
acid. Also consistent with data reported by Robinson and Panaccione (2014), there was an absence
of dihydroelymoclavine and other intermediates in our transformants, further indicating that CloA
binds festuclavine and completes successive oxidations, before releasing dihydrolysergic acid. It
was also discovered that CloA from C. gigantea was able to utilize both festuclavine and
agroclavine as substrates, meaning that it is capable of functioning in both dihydrolysergic acid
and lysergic acid pathways.
Due to the unexpected production of dihydrolysergic acid instead of dihydroelymoclavine,
alkaloids from samples of C. gigantea sclerotia were analyzed. Surprisingly, in contrast to the
findings of Agurell and Ramstad (1965), data from three different sclerotia showed accumulation
of dihydrolysergic acid, which was not thought to be produced in nature. The data however,
supported our findings that the product of cloA was responsible for the production of
dihydrolysergic acid. Additionally, having dihydrolysergic acid as the ergot alkaloid pathway end
product in the fungus was supported by DNA sequence analysis revealing that the gene encoding
lysergyl peptide synthetase subunit 1, lpsA, had a frame shift mutation, likely abolishing the genes
function. It was predicted that the correction of the lpsA mutation would further the dihydrolysergic
acid pathway to dihydroergosine, as observed by Barrow et al. (1974) for the related fungus C.
africana. Nevertheless, C. gigantea is the first discovered ergot fungus to have dihydrolysergic
acid as its pathway end product.
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Furthermore, after cloA was sequenced from cDNA reverse-transcribed from mRNA from
the mutant strains, it was discovered that about half of our mRNA was fully processed, containing
no introns, whereas the other half of mRNA still contained one of the seven introns, specifically
intron four. This discovery was not surprising, considering some of the cloA introns in C. gigantea
had unusual 3’ splice junctions, with polyA chains followed by a guanine, instead of the
conventional YAG. These unusual 3’ splice junctions make it plausible that the host strain, N.
fumigata, might have problems recognizing the 3’ splice and fail to splice out the intron. An intronfree version of cloA to see if the removal of the fourth intron would have an effect on the production
of dihydrolysergic acid. The constructs were successfully transformed and still produced
dihydrolysergic acid, however there was not a significant difference between the yields in ANOVA
(p = 0.58). As a result, it could be concluded that the retention of intron four did not have an effect
on the production of dihydrolysergic acid.
Additionally, it was questioned whether a stronger promoter would assist in increasing the
expression of cloA, hopefully increasing the turnover of dihydrolysergic acid. The intron-free
version of cloA was expressed from an N. fumigata glyceraldehyde-3-phospate dehydrogenase
(gpdA) promoter, which was assumed to be stronger than the N. fumigata easA-easG bidirectional
promoter, due to its original role for expressing a gene important for glycolysis. These mutant
strains also produced dihydrolysergic acid, however there was not a significant difference between
the yield produced by this strain compared yield produced by the original strain in ANOVA (p =
0.75). As a result, it could be concluded that a different promoter did not have a significant effect
on the production of dihydrolysergic acid.
Moreover, since Robinson and Panaccione (2014) coexpressed CloA with the
oxidoreductase, EasA from the same organism, it was questioned whether CloA functionally
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required coexpression with a species specific EasA to more efficiently generate dihydrolysergic
acid. The coexpression of cloA and easA both from C. gigantea in an N. fumigata easA KO
produced two-fold more dihydrolysergic acid (p = 0.006), indicating that the two enzymes may
interact in the pathway and that cloA from C. gigantea may function better with easA from C.
gigantea rather than easA from N. fumigata. This yield was significantly different from the original
yield in ANOVA, however it is important to note that the overall yield was still low.
Similarly, it was also predicted that the enzymes and substrates may be localized in separate
compartments. To test this, the transformants were homogenized and incubated with tween, and
either 0.1 M phosphate buffer (pH = 7.6) or 0.1 M phosphate buffer (pH = 7.6) supplemented with
NADPH (7.5 mg/mL). These homogenized solution incubated with 0.1 M phosphate buffer
supplemented with NADPH was significantly different in production of dihydrolysergic acid from
the control in ANOVA (p = 0.02). However, it cannot be concluded if the enzymes may be
localized in a separate compartment than the substrate or if the addition of NADPH helped in the
production. It is also important to note that the overall yield from this experiment was also low.
Another possibility that could be effecting the expression of cloA and/or the turnover of
dihydrolysergic acid is the random integration of the constructs into the genome, as a result of our
traditional transformation methods. Depending on where the construct is integrated it could be
highly expressed, lowly expressed, or not even expressed at all. Multiple transformants were
analyzed and their conversions of dihydrolysergic acid were averaged in attempts to minimize this
issue.
Lastly, it was questioned whether cloA from C. gigantea could oxidize substrates other
than festuclavine. Agroclavine was fed to the mutant strains and analyzed the ergot alkaloids
secreted into the media by HPLC. As a result, it was discovered that cloA from C. gigantea can
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oxidize agroclavine to lysergic acid, the same as cloA from Epichloë sp. Lp1 in Robinson and
Panaccione’s study (2014). This means that our allele of cloA is capable of oxidizing both
festuclavine and agroclavine, making it functional in both the dihydrolysergic acid pathway and
in the lysergic acid pathway.
Overall, the potential of the gene cloA from C. gigantea was unlocked to produce the
pharmaceutically important ergot alkaloid dihydrolysergic acid by genetically engineering a strain
of N. fumigata. Several significant pharmaceuticals, such as nicergoline (Sermion) and pergolide
(Permax), are currently being derived from lysergic acid, however semisynthetic derivation from
dihydroelymoclavine and/or dihydrolysergic acid would be more efficient. These drugs are
pharmaceutically relevant due to their structural similarities to neurotransmitters, allowing them
to treat cognitive and neurological disorders, such as migraines, dementia, Alzheimer’s, and
Parkinson’s disease (Morren and Galvez-Jimenez 2010;Baskys and Hou 2007;Winblad et al.
2007;Perez-Lloret and Rascol 2010). The generation of dihydrolysergic acid in such a fast-growing
organism would have a tremendous impact on drug modification and turnover for these
pharmaceuticals, when an alternative starting material is created. Additionally, understanding the
genes in the pathway could assist in producing libraries of ergot alkaloid derivatives with altered
pharmacology.
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